Mannkind Corporation

MNKD's staggering 193.7 P/E ratio reveals a market pricing in explosive growth that hasn't materialized yet—the stock trades at roughly 10x the pharma sector median despite single-digit revenue bases. With RSI at 71.1 signaling overbought conditions and a 9.65% short float, there's meaningful squeeze risk if momentum reverses, yet the valuation disconnect suggests the recent rally has detached from fundamentals. The modest short interest and distance from 52-week highs indicate this isn't a crowded bubble trade, but rather a speculative bet on binary catalysts—likely hinged on Afrezza adoption or pipeline breakthroughs. Without those catalysts delivering tangible revenue acceleration, the P/E compression risk is substantial.